GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (MEX:LABB) » Definitions » Revenue

Genomma Lab InternacionalB de CV (MEX:LABB) Revenue : MXN16,486 Mil (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Genomma Lab InternacionalB de CV Revenue?

Genomma Lab InternacionalB de CV's revenue for the three months ended in Mar. 2024 was MXN4,197 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was MXN16,486 Mil. Genomma Lab InternacionalB de CV's Revenue per Share for the three months ended in Mar. 2024 was MXN4.06. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was MXN16.94.

Warning Sign:

Genomma Lab Internacional SAB de CV revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Genomma Lab InternacionalB de CV was -0.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 9.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Genomma Lab InternacionalB de CV's highest 3-Year average Revenue per Share Growth Rate was 56.30% per year. The lowest was 2.10% per year. And the median was 10.30% per year.


Genomma Lab InternacionalB de CV Revenue Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Revenue Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,712.89 13,870.15 15,487.06 16,819.91 16,467.13

Genomma Lab InternacionalB de CV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,178.23 4,370.51 4,393.24 3,525.15 4,197.32

Competitive Comparison of Genomma Lab InternacionalB de CV's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Revenue distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Revenue falls into.



Genomma Lab InternacionalB de CV Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN16,486 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomma Lab InternacionalB de CV  (MEX:LABB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Genomma Lab InternacionalB de CV Revenue Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV (MEX:LABB) Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovalí Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Genomma Lab InternacionalB de CV (MEX:LABB) Headlines

No Headlines